Compare TIC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIC | ZYME |
|---|---|---|
| Founded | 1991 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | TIC | ZYME |
|---|---|---|
| Price | $9.55 | $26.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $14.17 | ★ $28.50 |
| AVG Volume (30 Days) | ★ 3.6M | 1.9M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,284,070,000.00 | $134,481,000.00 |
| Revenue This Year | $41.97 | $64.45 |
| Revenue Next Year | $42.94 | $67.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 16.15 | ★ 116.21 |
| 52 Week Low | $8.76 | $9.03 |
| 52 Week High | $14.94 | $28.49 |
| Indicator | TIC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 36.46 | 68.38 |
| Support Level | $8.81 | $24.83 |
| Resistance Level | $9.77 | $28.49 |
| Average True Range (ATR) | 0.39 | 1.57 |
| MACD | 0.09 | 0.15 |
| Stochastic Oscillator | 75.38 | 70.98 |
TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.